Paradigm submits comment letter to the U.S. Treasury Department regarding state-level regulatory path for the GENIUS Act
ChainCatcher reports, according to the official blog, Paradigm has submitted a comment letter to the US Department of the Treasury regarding rulemaking for the state-level regulatory pathway under the GENIUS Act. Paradigm supports the core framework of the proposal but points out that, unless four issues are amended, state-level channels will not effectively serve issuers. First, the proposal anchors the federal framework to OCC regulations that have not yet been finalized, requiring states and issuers to plan against an undetermined benchmark, directly hindering market access; the Treasury should not finalize this rule before OCC implementation rules are finalized. Second, the proposal requires unanimous agreement from the heads of the Treasury, the Federal Reserve, and the FDIC to certify state systems, but does not set a decision deadline, a standard for explaining vetoes, or a mechanism to prevent any single member from indefinitely blocking certification. Paradigm suggests establishing a 180-day decision deadline, creating a process for supplemental amendments, and requiring specific explanations for vetoes. Third, the proposal mandates state systems to require 12 months’ operating expenses in reserve funds, which may crowd out early-stage issuers; it is recommended that states be allowed to adjust reserve requirements based on issuer scale and risk profile. Fourth, the proposal fails to sufficiently preempt hostile actions by individual states, and this loophole must be addressed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
